Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dongrui Wang

Showing results (61-70 of 88) with videos related to

Pageof 9
Sort By:
Advanced Materials (Deerfield Beach, Fla.)|January 5, 2023
Electrochemical Replication and Transfer for Low-Cost, Sub-100 nm Patterning of Materials on Flexible SubstratesZijian Chen, Xi Lu, Huixin Wang, et al.
Eclinicalmedicine|May 30, 2023
Safety and efficacy of CRISPR-based non-viral <i>PD1</i> locus specifically integrated anti-CD19 CAR-T cells in patients with relapsed or refractory Non-Hodgkin's lymphoma: a first-in-human phase I studyYongxian Hu, Cheng Zu, Mingming Zhang, et al.
Leukemia|July 3, 2026
CD7 chimeric antigen receptor T cells in patients with relapsed or refractory CD7-positive acute myeloid leukemiaMingming Zhang, Lianxuan Liu, Shan Fu, et al.
JAMA Oncology|October 8, 2020
Systemic Anti-PD-1 Immunotherapy Results in PD-1 Blockade on T Cells in the Cerebrospinal FluidJana Portnow, Dongrui Wang, M Suzette Blanchard, et al.
Cancer Immunology Research|March 21, 2019
IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory PhenotypeDarya Alizadeh, Robyn A Wong, Xin Yang, et al.
Nature Communications|May 18, 2024
Hsc70 promotes anti-tumor immunity by targeting PD-L1 for lysosomal degradationXiaoyan Xu, Tingxue Xie, Mengxin Zhou, et al.
Nature Communications|July 10, 2023
ARIH1 activates STING-mediated T-cell activation and sensitizes tumors to immune checkpoint blockadeXiaolan Liu, Xufeng Cen, Ronghai Wu, et al.
Eclinicalmedicine|January 11, 2024
Donor-derived Anti-CD19 CAR T cells GC007g for relapsed or refractory B-cell acute lymphoblastic leukemia after allogeneic HSCT: a phase 1 trialYi Luo, Lei Gao, Jia Liu, et al.
Cancer Research Communications|March 27, 2023
Inclusion of 4-1BB Costimulation Enhances Selectivity and Functionality of IL13Rα2-Targeted Chimeric Antigen Receptor T CellsRenate Starr, Brenda Aguilar, Diana Gumber, et al.
The Lancet. Haematology|February 1, 2023
GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trialMingming Zhang, Guoqing Wei, Linghui Zhou, et al.
Pageof 9

Showing results (61-70 of 88) with videos related to

Sort By:
Pageof 9
Advanced Materials (Deerfield Beach, Fla.)|January 5, 2023
Electrochemical Replication and Transfer for Low-Cost, Sub-100 nm Patterning of Materials on Flexible SubstratesZijian Chen, Xi Lu, Huixin Wang, et al.
Eclinicalmedicine|May 30, 2023
Safety and efficacy of CRISPR-based non-viral <i>PD1</i> locus specifically integrated anti-CD19 CAR-T cells in patients with relapsed or refractory Non-Hodgkin's lymphoma: a first-in-human phase I studyYongxian Hu, Cheng Zu, Mingming Zhang, et al.
Leukemia|July 3, 2026
CD7 chimeric antigen receptor T cells in patients with relapsed or refractory CD7-positive acute myeloid leukemiaMingming Zhang, Lianxuan Liu, Shan Fu, et al.
JAMA Oncology|October 8, 2020
Systemic Anti-PD-1 Immunotherapy Results in PD-1 Blockade on T Cells in the Cerebrospinal FluidJana Portnow, Dongrui Wang, M Suzette Blanchard, et al.
Cancer Immunology Research|March 21, 2019
IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory PhenotypeDarya Alizadeh, Robyn A Wong, Xin Yang, et al.
Nature Communications|May 18, 2024
Hsc70 promotes anti-tumor immunity by targeting PD-L1 for lysosomal degradationXiaoyan Xu, Tingxue Xie, Mengxin Zhou, et al.
Nature Communications|July 10, 2023
ARIH1 activates STING-mediated T-cell activation and sensitizes tumors to immune checkpoint blockadeXiaolan Liu, Xufeng Cen, Ronghai Wu, et al.
Eclinicalmedicine|January 11, 2024
Donor-derived Anti-CD19 CAR T cells GC007g for relapsed or refractory B-cell acute lymphoblastic leukemia after allogeneic HSCT: a phase 1 trialYi Luo, Lei Gao, Jia Liu, et al.
Cancer Research Communications|March 27, 2023
Inclusion of 4-1BB Costimulation Enhances Selectivity and Functionality of IL13Rα2-Targeted Chimeric Antigen Receptor T CellsRenate Starr, Brenda Aguilar, Diana Gumber, et al.
The Lancet. Haematology|February 1, 2023
GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trialMingming Zhang, Guoqing Wei, Linghui Zhou, et al.
Pageof 9